References
- The Use of Physiologically Based Pharmacokinetic Analyses – Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls. Guidance for Industry. Draft Guidance. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), October 2020. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-physiologically-based-pharmacokinetic-analyses-biopharmaceutics-applications-oral-drug-product. [Last accessed on 15 December 2020].
- Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMA), December 2018. Available from: https://www.ema.europa.eu/documents/scientific-guideline/guideline-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation_en.pdf. [Last accessed on 15 December 2020].
- Bermejo M, Hens B, Dickens J, et al. A mechanistic physiologically-based biopharmaceutics modeling (PBBM) approach to assess the in vivo performance of an orally administered drug product: from IVIVC to IVIVP. Pharmaceutics. 2020;12(1):74.
- Konstantinidis IL, Dressman J. Physiologically based pharmacokinetic/pharmacodynamic modeling to support waivers of in vivo clinical studies: current status, challenges, and opportunities. Mol. Pharmaceutics. 2020:18(1):1–17.
- Heimbach T, Suarez-Sharp S, Kakhi M, et al. Dissolution and translational modeling strategies toward establishing an in vitro-in vivo link-a workshop summary report. Aaps J. 2019;21(2):29.
- McAllister M, Flanagan T, Boon K, et al. Developing clinically relevant dissolution specifications for oral drug products - industrial and regulatory perspectives. Pharmaceutics. 2019;12(1):19.
- Jereb R, Opara J, Legen I, et al. In vitro-in vivo relationship and bioequivalence prediction for modified-release capsules based on a PBPK absorption model. AAPS PharmSciTech. 2019;21(1):18.
- Zhang X, Duan J, Kesisoglou F, et al. Mechanistic oral absorption modeling and simulation for formulation development and bioequivalence evaluation: report of an FDA public workshop. CPT Pharmacometrics Syst Pharmacol. 2017; 6(8):492–495.
- Li X, Yang Y, Zhang Y, et al. Justification of biowaiver and dissolution rate specifications for piroxicam immediate release products based on physiologically based pharmacokinetic modeling: an in-depth analysis. Mol Pharm. 2019;16(9):3780–3790.
- O'Neil MJ. The merck index: an encyclopedia of chemicals, drugs, and biologicals. NJ: Merck and Co., Inc, 2006.
- Peck AW. Clinical pharmacology of lamotrigine. Epilepsia. 1991; 32(s2):S9–S12.
- Argikar UA, Remmel RP. Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 2009; 39(5):355–363.
- Conner TM, Reed RC, Zhang T. A physiologically based pharmacokinetic model for optimally profiling lamotrigine disposition and drug-drug interactions. Eur J Drug Metab Pharmacokinet. 2019; 44(3):389–408.
- Baka E, Comer JEA, Novák KT. Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound. J Pharm Biomed Anal. 2008;46(2):335–341.
- Cohen AF, Land GS, Breimer DD, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther. 1987;42(5):535–541.
- Wootton R, Soul-Lawton J, Rolan PE, et al. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. Br J Clin Pharmacol. 1997;43(1):23–27.
- Guideline for good clinical practice E6(R2). EMA/CHMP/ICH/135/1995. Committee for Human Medicinal Products. European Medicines Agency, 2018. Available from https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf [Last accessed on 4 January 2021].
- DECLARATION OF HELSINKI. Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the WMA General Assembly, Seoul, Korea, October 2008. Available from: https://www.wma.net/wp-content/uploads/2016/11/DoH-Oct2008.pdf [Last accessed on 1 January 2021].
- Agarwal SP. Good Clinical Practices For Clinical Research In India. Central Drugs Standard Control Organization. Dte.GHS, Ministry of Health and Family Welfare, Government of India.28 November 2013. Available from: http://www.sgpgi.ac.in/sop/GCP-%20Indian.pdf [Last accessed on 1 January 2021].
- National Ethical Guidelines For Biomedical And Health Research Involving Human Participants. Indian Council of Medical Research. October 2017. Available from: https://ethics.ncdirindia.org//asset/pdf/ICMR_National_Ethical_Guidelines.pdf. [Last accessed on 1 January 2021].
- GastroPlusTM User Manual for version 9. 6. Lancaster, CA: Simulations Plus, 2018.
- Lu ATK, Frisella ME, Johnson KC. Dissolution modeling: factors affecting the dissolution rates of polydisperse powders. Pharm Res. 1993;10(9):1308–1314.
- Price PS, Conolly RB, Chaisson CF, et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol. 2003;33(5):469–503.
- Haddad S, Restieri C, Krishnan K. Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans. J. Toxicol. Environ. Heal. - Part A. 2001;64(6):453–464.
- Lukacova V, Parrot N, Lave T, et al. Poster Session Presented at: American Association of Pharmaceutical Scientists (AAPS). General approach to calculation of tissue:plasma partition coefficients for physio-logically based pharmacokinetic (PBPK) modeling. 2008;. Nov 17, Atlanta, GA.
- Extended Release Oral Dosage Forms: Development, Evaluation and Application of In Vitro/In Vivo Correlations. Food and Drug Administration. Guidance for Industry: 1997. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/extended-release-oral-dosage-forms-development-evaluation-and-application-vitroin-vivo-correlations. [Last accessed 15 December 2020].
- Guideline on quality of oral modified release products. European Medicines Agency2014. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-oral-modified-release-products_en.pdf [Last accessed 15 December 2020].
- Nguyen MA, Flanagan T, Brewster M, et al. A survey on IVIVC/IVIVR development in the pharmaceutical industry - Past experience and current perspectives. Eur J Pharm Sci. 2017;102:1–13.
- Suarez-Sharp S, Li M, Duan J, et al. Regulatory experience with In Vivo In Vitro Correlations (IVIVC) in new drug applications. Aaps J. 2016;18(6):1379–1390.
- Mitra A. Maximizing the role of physiologically based oral absorption modeling in generic drug development. Clin Pharmacol Ther. 2019;105(2):307–309.
- Margolskee A, Darwich AS, Galetin A, et al. Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions. Aaps J. 2016; 18(2):321–332.
- Physiologically Based Pharmacokinetic Analyses - Format and Content Guidance for Industry. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) August 2018. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/physiologically-based-pharmacokinetic-analyses-format-and-content-guidance-industry [last accessed 15 December 2020].